Large neutral amino acids in the treatment of phenylketonuria (PKU)
McDonald, J. David
Tyring, S. K.
MetadataShow full item record
Matalon, R.; Michals-Matalon, K.; Bhatia, G.; Grechanina, E.; Novikov, P.; McDonald, J. David; Grady, J.; Tyring, S. K.; Guttler, F. 2006. Large neutral amino acids in the treatment of phenylketonuria (PKU). Journal of Inherited Metabolic Disease, v.29 no.6 pp.732-738
Large neutral amino acids (LNAAs) have been used on a limited number of patients with phenylketonuria (PKU) with the purpose of decreasing the influx of phenylalanine (Phe) to the brain. In earlier studies on mice with PKU (ENU2/ENU2), LNAAs were given and a surprising decline in blood Phe concentrations was observed. The formula used in the mouse experiment (PreKUnil) lacked lysine. Therefore, a new formulation of LNAAs (NeoPhe) was developed, introducing changes in the concentration of some amino acids and adding lysine, so that such a mixture could be used in humans. The new formula was found to be effective in reducing blood Phe concentration in mice by about 50% of the elevated levels. Patients with PKU were given LNAAs and blood Phe concentrations were determined in an open-label study. Three centres—in Russia, the Ukraine and the USA—took part in the study. NeoPhe was given at 0.5 g/kg per day in three divided doses to eight subjects with PKU and at 1.0 g/kg per day to three patients, for one week. The NeoPhe resulted in decrease of elevated blood Phe by 50% in both groups. The preliminary data from this study are encouraging and a double blind placebo-controlled trial will be required to show long-term efficacy and tolerance of LNAAs in the treatment of PKU.
Click on the DOI link to access the article (may not be free).